Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 6/20 | 0.96 |
| ▸ | HTR7 known ✓ | P34969 | 5/20 | 0.61 |
| ▸ | HTR1A known ✓ | P08908 | 4/20 | 0.61 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 3/20 | 0.61 |
| ▸ | HTR3B known ✓ | O95264 | 3/20 | 0.61 |
| ▸ | HTR3A known ✓ | P46098 | 3/20 | 0.61 |
| ▸ | HTR3D known ✓ | Q70Z44 | 3/20 | 0.61 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 3/20 | 0.61 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 3/20 | 0.61 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.61 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.61 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.61 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.61 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.61 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.57 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.57 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.56 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6965723 | 1.00 | ADRB1 (0.96) | ADRB1HTR7HTR1AHTR3EHTR3B | |
| SCHEMBL29391951 | 0.98 | ADRB1 (1.00) | ADRB1HTR7HTR1AHTR3EHTR3B | |
| SCHEMBL81365 | 0.98 | ADRB1 (1.00) | ADRB1HTR7HTR1AHTR3EHTR3B | |
| SCHEMBL234093 | 0.91 | ADRB1 (0.87) | ADRB1HTR7HTR1AHTR3EHTR3B | |
| Bicarbonate SCHEMBL11624933 | 0.90 | ADRB1 (0.84) | ADRB1HTR7HTR1AHTR3EHTR3B | |
| SCHEMBL5540575 | 0.87 | ADRB1 (0.80) | ADRB1HTR7HTR1AHTR3EHTR3B | |
| Succinic Acid SCHEMBL7471098 | 0.85 | ADRB1 (0.74) | ADRB1HTR7HTR1AHTR3EHTR3B | |
| SCHEMBL10373770 | 0.84 | ADRB1 (0.74) | ADRB1HTR7MAPTALDH1A1KCNH2 | |
| SCHEMBL11103700 | 0.84 | ADRB1 (0.74) | ADRB1HTR7MAPTALDH1A1KCNH2 | |
| SCHEMBL11714795 | 0.83 | ADRB1 (0.72) | ADRB1HTR7HTR1AHTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324216-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| EP-2234992-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2012-02-22 | — | — | EP | disclosed |
| US-8093248-B2 | Compounds useful for the treatment of conditions associated with weight gain | ASTRAZENECA AB (PUBL) (SE) | 2012-01-10 | — | — | US | disclosed |
| US-8003649-B2 | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155 | ASTRAZENECA AB (SE) | 2011-08-23 | — | — | US | disclosed |
| US-7842693-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| EP-2235010-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| EP-2234992-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| US-20100240618-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| US-20090281087-A1 | Compounds II | BIOVITRUM AB (SE) | 2009-11-12 | — | — | US | disclosed |
| US-5136037-A | 3-(4-substituted-4-piperazinyl)butyl-4-thiazolidinone and related compounds | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1992-08-04 | — | — | US | disclosed |
| US-5037984-A | Anticonvulsants; anxiolytic agents | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1991-08-06 | — | — | US | disclosed |
| US-5001125-A | Anti-virally active pyridazinamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-03-19 | — | — | US | disclosed |
| EP-0156433-B1 | ANTI-VIRALLY ACTIVE PYRIDAZINAMINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-02-27 | — | — | EP | disclosed |
| US-4933453-A | ANTIPSYCHOTIC, ANALGESIC, ANTICONVULSANT, AND ANXIOLYTIC AGENTS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1990-06-12 | — | — | US | disclosed |
| EP-0333137-A1 | Arylpiperazinylalkoxy derivatives of cyclic imides, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1989-09-20 | — | — | EP | disclosed |
| EP-0316723-A1 | 3-[4(1-Substituted-4-piperazinyl)butyl]-4-thiazolidinones a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1989-05-24 | — | — | EP | disclosed |
| US-4826846-A | ANALGESIC, ANTIPSYCHOTIC | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1989-05-02 | — | — | US | disclosed |
| US-4780466-A | ANALGESICS, ANTIPSYCHOTIC AGENTS, ANXIOLYTIC AGENTS | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1988-10-25 | — | — | US | disclosed |
| EP-0156433-A2 | Anti-virally active pyridazinamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281087-A1 | Compounds II | GPR119, FABP4, LIPC | ADRB1 225/4885HTR7 922/4885HTR1A 1680/4885 |
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | AR, NR5A1, CYP17A1 | ADRB1 112/4885HTR7 522/4885HTR1A 571/4885 |
| US-20100240618-A1 | SUBSTITUTED PIPERAZINES | CCR1, CCR3, CCRL2 | ADRB1 230/4885HTR7 461/4885HTR1A 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.